Literature DB >> 1516597

Tumor necrosis factor alpha is associated with disease activity and the degree of anemia in patients with rheumatoid arthritis.

G Vreugdenhil1, B Löwenberg, H G Van Eijk, A J Swaak.   

Abstract

To elucidate the role of tumor necrosis factor alpha (TNF) in determining anemia of chronic disease (ACD) in rheumatoid arthritis (RA), 24 patients were studied for disease parameters, TNF serum levels and bone marrow for erythroid colony growth and compared with six controls. Serum TNF alpha was highest in ACD and correlated well with RA disease parameters. Both TNF and other RA disease parameters correlated inversely with degree of anemia. BFUe counts were lower in ACD, correlated positively with Hb and negatively with erythrocyte sedimentation rate (ESR). TNF reduced whereas anti-TNF upregulated in vitro erythroid colony counts. TNF production occurred in similar amounts in bone marrow cultures in the three groups. From these preliminary findings we conclude that ACD in RA correlates with by RA disease activity and that TNF may serve not only as an RA disease marker but also could be one of the factors mediating impaired erythropoiesis in ACD in active RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516597     DOI: 10.1111/j.1365-2362.1992.tb01495.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  22 in total

1.  Antioxidant levels represent a major determinant in the regenerative capacity of muscle stem cells.

Authors:  Kenneth L Urish; Joseph B Vella; Masaho Okada; Bridget M Deasy; Kimimasa Tobita; Bradley B Keller; Baohong Cao; Jon D Piganelli; Johnny Huard
Journal:  Mol Biol Cell       Date:  2008-11-12       Impact factor: 4.138

Review 2.  Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease.

Authors:  M Jongen-Lavrencic; H R Peeters; G Vreugdenhil; A J Swaak
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

Review 3.  Anaemia in inflammatory rheumatic diseases.

Authors:  Günter Weiss; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

4.  The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

Authors:  Daniel E Furst; Jonathan Kay; Mary Chester Wasko; Edward Keystone; Arthur Kavanaugh; Atul Deodhar; Frederick T Murphy; Jeanette H Magnus; Elizabeth C Hsia; Benjamin Hsu; Stephen Xu; Mahboob U Rahman; Mittie K Doyle
Journal:  Rheumatology (Oxford)       Date:  2013-07-09       Impact factor: 7.580

Review 5.  The erythroblastic island as an emerging paradigm in the anemia of inflammation.

Authors:  Jimmy Hom; Brian M Dulmovits; Narla Mohandas; Lionel Blanc
Journal:  Immunol Res       Date:  2015-12       Impact factor: 2.829

6.  Course and characteristics of anaemia in patients with rheumatoid arthritis of recent onset.

Authors:  H R Peeters; M Jongen-Lavrencic; A N Raja; H S Ramdin; G Vreugdenhil; F C Breedveld; A J Swaak
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

Review 7.  Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.

Authors:  Arturo J Martí-Carvajal; Luis H Agreda-Pérez; Ivan Solà; Daniel Simancas-Racines
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

8.  Serum pro-hepcidin could reflect disease activity in patients with rheumatoid arthritis.

Authors:  Hae-Rim Kim; Kyoung-Woon Kim; So-Young Yoon; Sang-Hyon Kim; Sang-Heon Lee
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

9.  Serum pro-hepcidin levels in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Suleyman Serdar Koca; Ahmet Isik; Bilal Ustundag; Kerem Metin; Kader Aksoy
Journal:  Inflammation       Date:  2008-02-16       Impact factor: 4.092

10.  Tumor necrosis factor priming of peripheral blood neutrophils from rheumatoid arthritis patients.

Authors:  I C Kowanko; A Ferrante; G Clemente; P P Youssef; M Smith
Journal:  J Clin Immunol       Date:  1996-07       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.